William Jl Rieflin

CIK: 0001182471

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LYCA

Lycia Therapeutics, Inc.

Director

LYEL

Lyell Immunopharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

LYCA
Lycia Therapeutics, Inc.
Oct 22, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20K shares-
LYCA
Lycia Therapeutics, Inc.
Aug 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
24.8K shares-
LYEL
Lyell Immunopharma, Inc.
Jun 10, 2026
Award(A)
Option (right to buy)
Direct
9.3K shares-
LYEL
Lyell Immunopharma, Inc.
May 15, 2025
Award(A)
Option (right to buy)
Direct
130K shares-

		Type	Shares	Price		Ownership
Oct 22, 2026	LYCA Lycia Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,000	-	-	Direct
Aug 11, 2026	LYCA Lycia Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	24,840	-	-	Direct
Jun 10, 2026	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	9,250	-	-	Direct
May 15, 2025	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	130,000	-	-	Direct

1-4 of 4 transactions

About RIEFLIN WILLIAM JL

RIEFLIN WILLIAM JL (SEC CIK 0001182471) files insider reports with the SEC as Director of Lycia Therapeutics, Inc. (LYCA) and Director of Lyell Immunopharma, Inc. (LYEL).

Signal8 holds 4 ownership filings by RIEFLIN WILLIAM JL (1 Form 3, 3 Form 4), filed between May 19, 2025 and Oct 26, 2026. Those filings report 4 transactions, from May 15, 2025 to Oct 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on RIEFLIN WILLIAM JL's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by RIEFLIN WILLIAM JL

Oct 22, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
Aug 11, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
Jun 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
May 15, 2025: Grant or award of LYEL derivative securities (Form 4, code A).

Other insiders filing for Lycia Therapeutics, Inc. (LYCA)

Venrock Healthcare Capital Partners III, L.P., 10% Owner
Versant Ventures VII GP, L.P., 10% Owner
Fischer Laurent, Director
Henderson Jane, Director
Touami Sofia, Chief Business Officer
Staben Steven, Chief Scientific Officer

How to read Form 4 transaction codes